BioNTech SE (BNTX : NASDAQ)
Common Stock
$97.64
USD
+0.74 (0.76%)
Last updated: 2026-10-05
Follow BNTX
BNTX
BioNTech SE
WealthAwesomePerformance
1 Day
+0.76%
1 Week
-1.45%
1 Month
-5.90%
YTD
+0.98%
Key Statistics
Market Cap
$24.53B
52W High
$124.00
52W Low
$79.52
P/E Ratio
-
50 Day MA
$98.52
200 Day MA
$97.70
Beta
1.25
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 10/5/2026 | $96.74 | $98.78 | $95.20 | $97.64 | $97.64 | 1,435,705 |
| 10/2/2026 | $97.35 | $98.00 | $96.22 | $96.90 | $96.90 | 681,400 |
| 10/1/2026 | $97.59 | $99.49 | $96.60 | $96.85 | $96.85 | 820,000 |
| 9/30/2026 | $98.28 | $99.14 | $96.90 | $98.30 | $98.30 | 845,100 |
| 9/29/2026 | $98.43 | $99.79 | $97.60 | $98.57 | $98.57 | 736,900 |
| 9/28/2026 | $97.00 | $100.21 | $96.64 | $99.08 | $99.08 | 781,200 |
| 9/25/2026 | $99.51 | $100.02 | $97.73 | $98.52 | $98.52 | 580,000 |
| 9/24/2026 | $97.62 | $99.93 | $97.05 | $99.26 | $99.26 | 803,400 |
| 9/23/2026 | $100.61 | $101.31 | $98.31 | $98.46 | $98.46 | 1,087,400 |
| 9/22/2026 | $98.00 | $102.23 | $97.46 | $100.87 | $100.87 | 1,050,500 |
Analyst Price Targets
Based on 20 analysts covering BNTX · as of Oct 6, 2026
Wall Street analysts forecast BNTX stock price to rise 18.6% over the next 12 months.
Consensus
Buy4.30 / 5.00
Avg. Target
US$115.78
+18.6% Upside
Previously US$116.14 on Oct 5, 2026
Current Price
US$97.64
Last close
Analyst Breakdown (20 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BNTX's historical volatility
30-Day Vol
37.7%
Annualized
90-Day Vol
47.1%
Annualized
Trend (90d)
+27.3%
Annualized drift
90d Mean
US$107.65
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$100.87 | US$88.56 – US$114.88 |
| 60 trading days | US$104.20 | US$86.69 – US$125.26 |
| 90 trading days | US$107.65 | US$85.93 – US$134.86 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About BioNTech SE
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.
Financials
- Revenue (TTM)
- $2.65B
- EBITDA
- $-1.38B
- Profit Margin
- -63.64%
- ROE (TTM)
- -9.30%
- EPS (Diluted)
- -7.83
- Book Value
- 79.55
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About BNTX.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| GUTS | Fractyl Health, Inc. Common Stock | $4.56 | +1020.39% |
| CMND | Clearmind Medicine Inc. Common Shares | $6.00 | +739.16% |
| AMPGZ | Amplitech Group, Inc. Series B Right | $0.24 | +74.48% |
| VEEA | Veea Inc. | $5.72 | +71.77% |
| PDSB | PDS Biotechnology Corp | $1.20 | +60.21% |
| BEAT | Heartbeam Inc | $0.65 | +50.39% |
| RITRF | Reitar Logtech Holdings Limited | $0.01 | +42.86% |
| QTEX | QTREX Quantum Ltd. | $1.54 | +40.00% |
BNTX.US news timeline
1 article covering BNTX.US, most recent first
Latest